Efficacy and safety of OK‐432 immunotherapy of lymphatic malformations

Smith, Mark C.; Zimmerman, Mark; Burke, Diane K.; Bauman, Nancy M.; Sato, Yutaka; Smith, Richard J.

doi:10.1002/lary.20041

Cited by 140 publications

(135 citation statements)

References 15 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Whereas, in this prospective survey, no microcystic LM responded properly to the sclerotherapy (6). A study with repeated sclerotherapy using bleomycin A5 hydrochloride presented 78.57% effectiveness in a microcystic LM cohort.…”

Section: Introductionmentioning

confidence: 61%

Infusion Sclerotherapy of Microcystic Lymphatic Malformation: Clinico-Radiological Mid-Term Results

Lee

Chung

et al. 2016

J Korean Soc Radiol

View full text Add to dashboard Cite

Purpose:A new sclerotherapy technique by slow mechanical infusion of sclerosant was validated for treatment of microcystic lymphatic malformation (mLM). Materials and Methods: Seventeen consecutive patients with mLM in extremities, cervicofacial area, and trunk were included (21.8 ± 21.5 years old, male:female = 5:12). All patients diagnosed as mLM were included. A total 4-32 mL 20-38% OK-432 solution was mechanically infused at the rate of 10 mL/hour into the mLM lesions. The treatment effect was estimated clinic-radiologically at the 4-month follow-up. Repeated sclerotherapy followed in the 6th month, if required. The therapeutic effect was evaluated using quantitative ultrasonographic examination including soft tissue thickness, cyst size and number. Results: In 17 patients, total 31 infusion sclerotherapy sessions were performed and monitored for 425 ± 266 days. Fifteen patients (88%) showed improvement in all symptoms, signs, and ultrasonographic findings. In all cases, at least one finding presented improvement. The maximal number of cysts per ultrasonographic window and maximal diameter of the largest cyst decreased by 57 ± 57% and 51 ± 67%, respectively (p = 0.102, 0.004). The soft tissue thickness decreased by 18 ± 15% (p < 0.01). No significant complications such as distal lymphedema or skin necrosis occurred. Conclusion: Infusion sclerotherapy is a safe and effective treatment technique for microcystic LM, with improved outcome.

show abstract

Section: Introductionmentioning

confidence: 61%

Infusion Sclerotherapy of Microcystic Lymphatic Malformation: Clinico-Radiological Mid-Term Results

Lee

Chung

et al. 2016

J Korean Soc Radiol

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15] However, several authors have suggested that sclerotherapy may be a more appropriate first-line therapy. 16,17 Although sclerotherapy is now well established in the treatment of neonatal and paediatric cystic hygromas, there have been relatively few cases reported of its use in adult patients. Some success has been reported in small numbers of adults with sclerotherapy agents such as OK-432.…”

Section: Discussionmentioning

confidence: 99%

“…18 Caution has been urged with the use of agents such as OK-432 which induce a local immune response that often results in a rapid temporary increase in the size of the cystic hygroma. 17,18 Smith et al compared results from their large-scale trial of OK-432 with pooled results from large surgical case series reported in the literature and reported greater success rates and lower occurrence of major complications with OK-432 sclerotherapy compared with surgical excision. 17 In addition, clinical success of OK-432 treatment was defined as a greater than 60% reduction in size.…”

Section: Discussionmentioning

confidence: 99%

“…17,18 Smith et al compared results from their large-scale trial of OK-432 with pooled results from large surgical case series reported in the literature and reported greater success rates and lower occurrence of major complications with OK-432 sclerotherapy compared with surgical excision. 17 In addition, clinical success of OK-432 treatment was defined as a greater than 60% reduction in size. 17 This may leave a substantial proportion of the lesion in situ and the acceptability of this may depend on the exact location and relations of the tumour.…”

Section: Discussionmentioning

confidence: 99%

“…17 In addition, clinical success of OK-432 treatment was defined as a greater than 60% reduction in size. 17 This may leave a substantial proportion of the lesion in situ and the acceptability of this may depend on the exact location and relations of the tumour. It is therefore difficult to apply these results to our case of an adult patient with a lesion in close relation to several important structures in the neck.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations